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ABSTRACT
The aim of this study was to comparatively investigate the effects of 5-azacytidine-C (5-Aza), trichostatin-
A (TSA), and all-trans retinoic acid (ATRA) on mRNA expressions of Na/I symporter (NIS), thyroglobu-
lin (Tg), thyroid peroxidase (TPO), and thyroid stimulating hormone receptor (TSH-R), and radioiodine
(RAI) uptake in cancer (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines. Cell lines were treated
with 10 ng/mL of TSA, 5 M of 5-Aza, and 1 M of ATRA, according to the MTT (methyl-thiazol-tetra-
zolium) test results. Additionally, recombinant thyroid stimulating hormone (rTSH) was also applied, with
a selected dose of 100 ng/mL. Following the treatment, NIS, Tg, TPO, and TSH-R mRNA levels were de-
tected by real-time–polymerase chain reaction (RT-PCR) and RAI uptakes were measured by using a well
counter as the counts/cell number. 5-Aza increased TSH-R mRNA expression in both of the cell lines and
decreased TPO, NIS, and Tg mRNA levels in the cancer cell line. In the normal thyroid cell line, 5-Aza
increased TPO mRNA levels 2-fold and made no differences in NIS and Tg mRNA levels. TSA treatment
repressed NIS and Tg mRNA levels, and made no differences on other thyroid specific genes investigated
in the cancer cell line. In the normal thyroid cell line, TSA increased TSH-R mRNA levels in 72 hours
and created no important differences in other genes. ATRA repressed the TSH-R mRNA levels in the nor-
mal thyroid cell line and increased the TPO and Tg mRNA levels slightly in both cell lines. Furthermore,
in short-term treatment, ATRA repressed NIS gene expression slightly, but in the long term, this repres-
sion turned to basal levels. 5-Aza, TSA, and ATRA did not make any differences in RAI uptake in the can-
cer cell line, but rTSH increased RAI uptake significantly. In the normal thyroid cell line, TSA and ATRA
decreased RAI uptake (to 1/10 and 1/2, respectively), but 5-Aza and rTSH increased RAI uptake signifi-
cantly (2- and 4-fold, respectively). We have shown an increase in TSH-R gene expression and radioio-
dine uptake with 5-Aza. Further in vitro and in vivo studies are needed to support our findings and the
potential clinical use of this agent.
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INTRODUCTION
The main therapy modalities in the treatment of
the patients suffering from thyroid cancer are sur-
gery and radioiodine (RAI) therapy.1,2 The nor-
Address reprint requests to: Ömer Ugur; Department of
Nuclear Medicine, Hacettepe University Faculty of Medi-
cine, TR-06100, Sihhiye, Ankara, Turkey; Tel.: 90-312-
3051336; Fax: 90-312-3093508
E-mail: ougur@hacettepe.edu.tr
mal thyroid cells have certain specific properties,
such as RAI uptake, sodium iodine symporter
(NIS), thyroid peroxidase (TPO) activity, thy-
roglobulin (Tg) synthesis, and thyroid-stimulat-
ing hormone receptors (TSH-Rs). During the ma-
lign dedifferentiation process, these properties
were lost, which led to a problematic patient
group who had residual thyroid cancer with ele-
vated Tg levels but negative I-131 scintigraphy.
The discouraging results of non-RAI treatment
methods in these patients led the researchers to
seek out new methods to reestablish RAI uptake.3
For this purpose retinoic acids (RAs) were one
of the first agents to be used for their redifferen-
tiation induction properties. Simon et al. showed
an increase in RAI uptake in 8 of 20 patients fol-
lowing treatment with 1.5 mg/kg of RA.4 How-
ever, other studies did not support these initially
encouraging results.5 Therefore, new innovative
methods are needed to reestablish radioiodine up-
take in the dedifferentiated thyroid tumors. 5-aza-
cytidine, a DNA methyltransferase inhibitor, is a
promising agent for this purpose, which prevents
the methylation of certain genes and modulates
their activities.6 Initial experimental studies are
encouraging. Venkataraman et al. was able to re-
store hNIS mRNA expression in four cell lines
and iodide transport in two cell lines following
treatment with 5-azacytidine.7 Trichostatin A,
which is a histone deacetylase inhibitor, was also
tried to reestablish radioiodine uptake. Zarnegar
et al. showed an increase in mean NIS gene ex-
pression following treatment with trichostatin A.8
After these successful preclinical studies, a his-
tone deacetylase inhibitor, suberoylanilide hy-
droxamic acid (SAHA), was used orally and es-
tablished radioiodine uptake in 1 of 3 patients.9
In the literature, the studies with these agents are
limited and the differential effects of these drugs
on thyroid-specific genes in different tumoral and
normal thyroid cell lines need further clarifica-
tion. In this study, we investigated the role of
these gene modulators on the mRNA expressions
of NIS, Tg, TPO, TSH-R, and RAI uptake in can-
cer and normal thyroid cell lines.
MATERIAL AND METHODS
Cell Lines and Chemicals
B-CPAP is a tumoral cell line derived from a 76-
year-old patient with metastatic papillary cancer and
was obtained from DSMZ (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmBH
[German Collection of Microorganisms and Cell
Cultures; Braunschweig, Germany).10 Nthy-ori 3-1
is a normal thyroid follicular epithelial cell line,
immortalized by SV-40 and obtained from ECACC
(European Collection of Cell Cultures; Wiltshire,
United Kingdom).11 Both cell lines were grown in
RPMI 1640 medium supplemented with 2 mM of
glutamine and 10% fetal bovine serum (FBS) at
37°C and 5% CO2. The reagents used, 5-Aza, TSA,
ATRA, RPMI 1640, N,N dimetilformamid (DMF),
FBS, penisilin-streptomisin and L-glutamine, were
purchased from Sigma Chemical Company (St.
Louis, MO) and recombinant TSH (rTSH); (Thy-
rogen®) was obtained from the Genzyme corpora-
tion (Cambridge, MA).
MTT (Methyl-Thiazol-Tetrazolium) Test
Cells were placed in 96-well plates at a density
of 8000 cells/well for 24 hours and 2000
cells/well for 48- and 72-hour incubations. Fol-
lowing treatment with different doses of TSA
(10–50 ng/mL), 5-Aza (1-50 M), and ATRA
(0,01-100 M) for 24, 48, and 72 hours, the me-
dia were removed and the cells were incubated
with MTT (concentration of 1 mg/ml) for 4 hours.
Viable cells convert yellow-colored MTT to vi-
olet-colored formazan crystals by using the mi-
tochondrial succinate dehydrogenase. These for-
mazan crystals were dissolved in dimethyl
sulfoxide (DMSO; pH, 4.7), prepared after being
dissolved in 45% DMF, and the amount of for-
mazan crystals reflecting cellular growth and vi-
ability was determined quantitatively by ab-
sorbance measurements in spectrophotometric
assays. The sublethal maximum doses for every
gene modulator were determined according to the
MTT results. rTSH levels were determined by the
maximum effective dose defined (100 ng/mL) in
the literature and applied for 4 and 9 days.12
RNA Isolation and RT-PCR 
(Real-Time-Polymerase Chain Reaction)
After treatment with gene modulators, RNA iso-
lation from the cells were made by a Qiagen
RNAeasy kit (Qiagen Inc., Valencia, CA), using
the “Spin” protocol. For RT-PCR, a Quantitech
RT-PCR kit obtained from Qiagen Inc. and
primers and probes obtained from the Motek
company (Istanbul, Turkey) were used. The dyes
used in the probes were black hole and FAM. RT-
PCR was done in an ICycler thermal cycler (Bio-
Rad; Hercules, CA) compatible with the optic
detection system, iCycler iQ (Biorad). Gene ex-
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pression studies were repeated three times and
specific gene expressions were normalized with
GADPH (glyceraldehyde-3-phosphate dehydro-
genase) mRNA. Expression results were calcu-
lated in terms of Ct values and relative gene ex-
pression. Ct values represent the value of cycles
that the cells require to reach the threshold gene
expression, and these values were inversely cor-
related with gene expression. The relative gene
expression was calculated with the formula, Ct 
Ct,target  Ct,GAPDH (Ct)  Ct,drug  Ct,control
2(Ct)  relative expression, and directly pro-
portional to the gene expression.
Iodide Uptake
Two (2)  105 cells/well were plated in 24-well
plates and cultured with RPMI 1640 medium con-
taining 10% FBS. Following treatment, for 3 days
the cells were, washed with Hanks’ balanced salt
solution (HBSS) and incubated for 1 hour at 37°C
with 500 mL of HBSS containing 0.1 mCi of car-
rier-free NaI125 (Cisbio; Bagnols/Cèze Cedex,
France) and 10 mM of NaI. For perchlorate inhi-
bition studies, NaClO4 was added as a solution in
HBSS, with a final concentration of 30 M, im-
mediately following the addition of radiolabeled io-
dine. Reactions were rapidly terminated by re-
moving the radioactive HBSS and washing the
cells twice with ice-cold HBSS. The cells were then
extracted following solubilization with 90% etha-
nol for 30 minutes, and radioactivity was measured
by a gamma counter.13,14 The RAI uptake values
were given in values presenting the specific uptake
that can be inhibited by NaClO4.
RESULTS
MTT Test
In the MTT tests, TSA and ATRA showed sim-
ilar death rates in both cells, but 5-Aza showed
toxicity only in the B-CPAP cell line but not in
Nthy-ori 3-1 (Mann-Whitney U test; p  0.029).
According to the MTT results, cells were treated
with the sublethal doses of 10 ng/mL for TSA, 5
M for 5-Aza, and 1 M for ATRA.
RT-PCR and RAI Uptake
Basal thyroid-specific gene expressions are given
in Table 1. In both cell lines, basal NIS and TSH-
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Table 1. Basal Levels of Thyroid Specific Gene Expressions
Bb Na Bb Na Bb Na Bb Na
Gene TSH-R TSH-R TPO TPO Tg Tg NIS NIS
Target Ct 31.9 29.0 29.0 35.5 42.0 27.2 32.6 31.3
GAPDH Ct 11.3 10.1 11.5 11.6 11.9 10.6 11.7 11.0
Target/GAPDH 2.83 2.90 2.52 3.06 3.52 2.56 2.78 2.84
TSH-R, thyroid-stimulating hormone receptor; TPO, thyroid peroxidase; Tg, thyroglobulin; NIS, Na/I symporter; Ct, value of
cycles cells require to reach threshold gene expression; GADPH, glyceraldehyde-3-phosphate dehydrogenase.
aNthy-ori 3-1.
bB-CPAP.
Table 2. Twenty-four (24), 48-, and 72-Hour Relative Expressions of Thyroid Specific Genes Are Shown After a 5-M 
5-azacytidine Application
Nthy-ori Nthy-ori Nthy-ori Nthy-ori BCPAP BCPAP BCPAP BCPAP
TPO NIS Tg TSH-R TPO NIS Tg TSH-R
Control 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
AZA 24 hours 2.14 0.57 0.38 4.29 0.35 0.31 1.15 1.15
AZA 48 hours 0.57 1.62 0.71 1.32 0.27 0.31 0.71 6.06
AZA 72 hours 0.47 0.81 1.15 0.87 0.38 0.31 0.62 2.46
TPO, thyroid peroxidase; NIS, Na/I symporter; Tg, thyroglobulin; TSH-R, thyroid-stimulating hormone receptor; AZA, 
azacytidine.
R mRNA levels were similar, but basal TPO ex-
pression was higher in the B-CPAP cell line and
Tg expression was higher in the Nthy-ori 3-1 cell
line. 5-Aza increased TSH-R mRNA expression
in both of the cell lines and decreased TPO, NIS,
and Tg mRNA levels in the cancer cell line. In
the normal thyroid cell line, 5-Aza increased TPO
mRNA levels 2-fold and made no differences in
NIS and Tg mRNA levels (Table 2). TSA treat-
ment repressed NIS and Tg mRNA levels and
made no changes on other thyroid-specific genes
that were investigated in the cancer cell line. In
the normal thyroid cell line, TSA increased TSH-
R mRNA levels in 72 hours and created no im-
portant differences in other genes (Table 3).
ATRA repressed the TSH-R mRNA levels in the
normal thyroid cell line and increased the TPO
and Tg mRNA levels slightly in both cell lines.
Furthermore, in the short-term treatment, ATRA
repressed NIS gene expression slightly, but in the
long term, this repression turned to basal levels
(Table 4). TSA and ATRA did not make any sig-
nificant changes in RAI uptake in the cancer cell
line. 5-Aza slightly increased RAI uptake in the
cancer cell line, which was not statistically sig-
nificant (p  0.05). rTSH increased RAI uptake
significantly (Fig. 1). In the normal thyroid cell line,
TSA and ATRA decreased RAI uptake (to 1/10 and
1/2, respectively) but 5-Aza and rTSH increased
RAI uptake significantly (2- and 4-fold, respec-
tively) (Fig. 2) (p  0.011 and p  0.0001).
DISCUSSION
The treatment options for the patients who had
residual thyroid cancer, but negative I-131
scintigraphy, were limited. Several authors sug-
gested at least one empirical high-dose RAI treat-
ment, and if there was an RAI uptake in post-
therapy images and/or a decrease in Tg levels,
then further therapy with RAI would be war-
ranted.15 If there was no response to empirical
RAI therapy, chemotherapy and/or radiotherapy
could be tried. These treatments were used only
for palliative purposes owing to the low success
and high side-effect rate. In the literature, adria-
mycin treatment was reported to have a 31% and
37% partial response rate.16,17 These inadequate
response rates led the researchers to seek out new
methods to reestablish RAI uptake in tumor cells.
RA was one of the first agents to be tried in the
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Table 3. Twenty-four (24), 48-, and 72-Hour Relative Expressions of Thyroid Specific Genes Are Shown After an
Application of 10 ng/mL of Trichostatin A
Nthy-ori Nthy-ori Nthy-ori Nthy-ori BCPAP BCPAP BCPAP BCPAP
TPO NIS Tg TSH-R TPO NIS Tg TSH-R
Control 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
TSA 24 hours 1.07 0.57 0.76 0.71 0.54 0.47 0.81 0.38
TSA 48 hours 0.33 1.87 0.31 0.76 1.07 0.23 0.11 1.00
TSA 72 hours 1.15 0.76 1.23 3.03 0.93 0.44 0.57 1.41
TPO, thyroid peroxidase; NIS, Na/I symporter; Tg, thyroglobulin; TSH-R, thyroid-stimulating hormone receptor; TSA, tri-
chostatin-A.
Table 4. Twenty-four (24), 48-, and 72-Hour Relative Expressions of Thyroid Specific Genes Are Shown After an
Application of 1 M of All-Trans Retinoic Acid
Nthy-ori Nthy-ori Nthy-ori Nthy-ori BCPAP BCPAP BCPAP BCPAP
TPO NIS Tg TSH-R TPO NIS Tg TSH-R
Control 1.00 1.00 1.00 1.00 1.00 1.00 1.000 1.00
ATRA 24 hours 2.46 0.80 1.74 0.21 2.29 0.65 2.800 1.14
ATRA 48 hours 1.74 1.50 2.14 0.28 2.14 0.65 1.140 0.75
ATRA 72 hours 1.62 0.60 1.86 0.18 1.14 1.14 0.812 1.14
TPO, thyroid peroxidase; NIS, Na/I symporter; Tg, thyroglobulin; TSH-R, thyroid-stimulating hormone receptor; ATRA, all-
trans retinoic acid.
Figure 1. Radioiodine uptake values after a 72-hour application of 1 M all-trans retinoic acid, 10 ng/mL of Trichostatin A, 5
M of 5-azacytidine, and 4- and 9-day application of 100 ng/mL of rTSH in B-CPAP cell line.
Figure 2. Radioiodine uptake values after a 72-hour application of 1 M of all-trans retinoic acid, 10 ng/mL of Trichostatin
A, 5 M of 5-azacytidine, and a 4- and 9-day application of 100 ng/mL of rTSH in the Nthy-ori 3-1 cell line.
reinduction of RAI uptake owing to its rediffer-
entiation effect.
In preclinical studies, Schmutzler et al. showed
an increase in NIS gene expression in FTC-133 and
238 follicular thyroid tumoral cell lines but no
change in anaplastic thyroid cell lines HTh74 and
C643 after treatment with 1 M all-trans retinoic
acid. In the same study, retinoic acid application
caused a decrease in NIS mRNA levels and iodide
uptake (38%) in normal rat thyroid cell line, FTRL-
5.18 In the Nthy-ori 3-1 cell line, ATRA repressed
TSH-R mRNA levels and showed an increase in
TPO and Tg mRNA levels in both cell lines (max-
imum, 2.5-fold). This increase in Tg mRNA levels
was also detected by Kurebayashi et al. in a recur-
rent thyoid cancer cell line (KTC-1).19 In the NIS
gene, ATRA treatment caused a minimal suppres-
sion in short-term incubation, but returned to nor-
mal in both cell lines (Table 4). In Nthy-ori 3-1
cells, ATRA supressed RAI uptake and had no sig-
nificant effect on B-CPAP cell lines. The supres-
sive effect of ATRA in normal cell lines is com-
patible with the results reported by Schmutzler et
al. in FTRL-5.18 This finding supports the idea that
ATRA shows different effects in the normal and
tumoral thyroid cell lines.
Haugen et al. showed that the receptors re-
sponsible for the action of RA, namely RAR
and RXR, were different in tumoral cell lines
and the RXR form was not found in normal cell
lines. As expected, RA treatment was found to
be only effective in tumors expressing RAR and
RXR.20 This literature finding may explain the
ineffectiveness of ATRA in the B-CPAP cell line,
which we used in our study. The differential ef-
fects of RA on different cell lines and genes need
to be confirmed by further molecular studies on
both receptor and gene bases.
In our study, 5-azacytidine showed toxicity
only in the B-CPAP cell lines, but not in the Nthy-
ori 3-1 cell line, according to the MTT test re-
sults (Mann-Whitney U test; p  0.029). In their
study, Schmelz et al. showed an increase in apop-
totic p21WAF gene expression following treat-
ment with the methylation inhibitor, 5-Aza-2-de-
oksysitidin, and this leads to death in apoptotic
myeloid leukemia cells.21 Szyf found that, con-
trary to tumoral cells, normal cell lines do not
show death after the inhibition of the methylation
enzyme. According to the authors, this was re-
lated with the absence of methylation in tumor
suppressor genes (p21).22
These literature results suggested a possible in-
active tumor suppressor gene in B-CPAP leading
to death after activation by methylation inhibi-
tion, which may explain our MTT test results. In
our study, 5-Aza increased TSH-R mRNA ex-
pressions in both cell lines (Table 2). This find-
ing is compatible with the findings by Xing et al.,
who showed a methylation of TSH-R in 23 of 39
(59%) papillary thyroid carcinomas and 7 of 15
(47%) follicular thyroid carcinomas.23 After
binding to its receptor, TSH starts a signaling
pathway, which increases the expression of thy-
roid-specific genes and RAI uptake. During the
dedifferentiation process, the tumoral cells lose
their TSH-R and grow independently.24 TSH-R
is thought to have functions other than the trans-
mission of TSH signal. Hoelting et al. found that
in most of the metastatic aggressive follicular
cancer cells, TSH-R was absent, and after trans-
fection of this receptor, the cells showed a de-
crease in invasion and growth capacity. The au-
thors concluded that the presence of TSH-R also
functions in the control of cell growth.25 In our
study, we have shown an increase in TSH-R by
5-Aza in the tumoral cell line. 5-Aza, by rein-
ducing the expression of TSH-R in the tumoral
cell line, may increase the effect of TSH, which
is crucial for RAI uptake but may also control
cell growth. In our study, 5-Aza increased TPO
mRNA levels 2-fold and made no significant dif-
ferences in NIS and Tg mRNA levels in the nor-
mal thyroid cell line. The increase in TPO mRNA
supported the increased RAI uptake in the nor-
mal thyroid cell line (p  0.011).
To our knowledge, this is the first study to
show the effects of 5-Aza in normal thyroid cells
and must be supported by further studies. 5-Aza
decreased TPO, NIS, and Tg mRNA levels in the
cancer cell line but slightly increased RAI uptake
in the cancer cell line, which was not statistically
significant (p  0.05). These results were con-
trary to the results of Venkataraman et al.7 show-
ing an increase in NIS mRNA and RAI uptake in
thyroid cancer cell lines following treatment with
5-Aza. This difference can be a result of differ-
ent thyroid cell lines, which may differ in their
methylation characteristics.
We chose the B-CPAP cell line for our exper-
imental model, which is a relatively differenti-
ated cell line, as determined by better basal thy-
roid-specific gene expression levels10,25–27 (Table
1) and it fits to the clinical scenario (relatively 
differentiated and preserved its genetic information
but lost its I-131 accumulation capacity). The 
cell lines with different genetic characteristics 
may respond differently to demethylating agents.
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Moreover, as shown by Venkatarman et al., the
effect of these agents were not solely dependent
on gene expression levels, but also to the activi-
ties of transcription factors, such as thyroid tran-
scription factor-1.7 So, the slight increase in RAI
uptake in our study can be attributed to the effect
of 5-Aza on these transcription factors.
For a further clarification of this issue, we sug-
gest an analysis of the tumor cell lines for their
methylation status at each gene level prior to a
treatment with demethylating agents. In our
study, TSA treatment repressed NIS and Tg
mRNA levels and made no changes to other thy-
roid-specific genes that were investigated in the
cancer cell line. In the normal thyroid cell line,
TSA increased TSH-R mRNA levels in 72 hours
and created no important differences in other
genes (Table 3). TSA did not make any changes
in RAI uptake in the cancer cell line. In the nor-
mal thyroid cell line, TSA decreased RAI uptake.
Contrary to our results, Zarnegar et al. found
that following treatment with TSA, NIS expres-
sion was increased 107- and 217-fold in papil-
lary, 39- and 58-fold in hurthle, and 459- and 781-
fold in follicular thyroid cancers.8
In the literature, all of the studies with TSA
were done with dedifferentiated cancers. The in-
effectiveness of TSA in our study and the de-
crease in RAI uptake in normal cells also sug-
gested in inverse relation with differentiation
status as proposed with RA. In our study, the only
benefit from TSA was a slight increase in TSH-
R expression, which was less significant than 5-
Aza. As expected, rTSH increased RAI uptake in
both cell lines (Figs. 1 and 2). The application of
rTSH, especially with the agents that increase
TSH-R, must be further evaluated for a possible
synergistic effect.
CONCLUSIONS
We have shown an increase in TSH-R gene ex-
pression and radioiodine uptake with 5-Aza. Fur-
ther in vitro and in vivo studies are needed to sup-
port our findings and the potential clinical use of
this agent.
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